Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium ...

Drug compounders aren’t ready to give up their ability to produce off-brand versions of Novo Nordisk’s weight-loss drug ...

Today we'll look at six European stocks that could continue outperforming in 2025. Some of these companies are available to ...

Eli Lilly & Co. will spend at least $27 billion to build four US manufacturing plants, the latest company to brace for the ...

The FDA recently removed semaglutide from its drug shortage list, which has not been considered commercially available since ...

A lawsuit challenges the FDA's decision to remove semaglutide from the shortage list, alleging it was arbitrary and harms ...

Eli Lilly ( LLY) announced Wednesday that it is ramping up US manufacturing, adding four new sites to help increase the ...

As high prices and supply issues drive consumers to alternative markets for GLP-1s, physicians aren’t too interested in using ...

It comes as companies work to build goodwill with Trump, who has emphasized reshoring manufacturing to the U.S. and reducing ...

If successful, Mankind’s drug would be the first oral small-molecule alternative, offering a pill-based treatment.

Some health experts have call for further investigation, as figures show 82 deaths with suspected links to slimming drugs ...

Eli Lilly & Co. said Tuesday it's cutting the price of single-dose vials of its Zepbound treatment for diabetes and obesity for patients who have to pay for the drug themselves. It said it will also ...